Northern Trust Corp Eliem Therapeutics, Inc. Transaction History

Northern Trust Corp

$709 Billion
Q2 2025

A detailed history of Northern Trust Corp transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 141,424 shares of ELYM stock, worth $581,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares

141,424

Previous 300,886 53.0%

Holding current value

$581,252

Previous $1.24 Million 52.99%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	N/A	-159,462 Reduced 53.0%	141,424 $581,000
Q1 2025 May 13, 2025	SELL	N/A	-12,952 Reduced 4.13%	300,886 $1.24 Million
Q4 2024 Feb 14, 2025	BUY	$4.11 - $5.42 $87,242 - $115,050	21,227 Added 7.25%	313,838 $1.29 Million
Q3 2024 Nov 13, 2024	BUY	$4.98 - $8.93 $1.23 Million - $2.21 Million	246,934 Added 540.61%	292,611 $1.49 Million
Q2 2024 Aug 14, 2024	BUY	$2.6 - $10.2 $5,743 - $22,531	2,209 Added 5.08%	45,677 $324,000
Q1 2024 May 14, 2024	SELL	$2.54 - $2.98 $13,319 - $15,627	-5,244 Reduced 10.77%	43,468 $119,000
Q4 2023 Feb 13, 2024	BUY	$2.45 - $2.85 $91,948 - $106,960	37,530 Added 335.63%	48,712 $131,000
Q2 2023 Aug 11, 2023	SELL	$2.34 - $3.72 $152 - $241	-65 Reduced 0.58%	11,182 $31,000
Q1 2023 May 15, 2023	SELL	$2.3 - $4.64 $568 - $1,146	-247 Reduced 2.15%	11,247 $32,000
Q2 2022 Aug 12, 2022	SELL	$2.77 - $8.4 $122,120 - $370,330	-44,087 Reduced 79.32%	11,494 $35,000
Q1 2022 May 13, 2022	SELL	$8.01 - $13.15 $45,769 - $75,139	-5,714 Reduced 9.32%	55,581 $466,000
Q4 2021 Feb 08, 2022	SELL	$8.61 - $20.47 $6,380 - $15,168	-741 Reduced 1.19%	61,295 $641,000
Q3 2021 Nov 15, 2021	BUY	$14.45 - $28.61 $896,420 - $1.77 Million	62,036 New	62,036 $1.12 Million

Others Institutions Holding ELYM

# of Institutions

Shares Held

49.5M

Call Options Held

Put Options Held

View Full List

About Eliem Therapeutics, Inc.

Ticker ELYM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,567,700
Market Cap $109M
Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...

More about ELYM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Eliem Therapeutics, Inc. Transaction History